SCHEMBL4583876

SCHEMBL4583876

CCc1ccsc1-c1cccs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 4/20 0.41
ADORA2A P29274 3/20 0.41
LTA4H P09960 2/20 0.40
ALDH1A1 P00352 8/20 0.38
KDM4E B2RXH2 7/20 0.38
MAPT P10636 5/20 0.38
HPGD P15428 3/20 0.38
RAB9A P51151 2/20 0.38
HTT P42858 1/20 0.38
RCE1 Q9Y256 1/20 0.38
NPC1 O15118 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
DPP4 P27487 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6239742 0.88 LTA4H (0.38) ADORA1ADORA2ALTA4HALDH1A1KDM4E
SCHEMBL4585925 0.85 LTA4H (0.38) ADORA1ADORA2ALTA4HALDH1A1KDM4E
SCHEMBL1224308 0.82 ADK (0.43) ADORA1ADORA2ALTA4HALDH1A1KDM4E
SCHEMBL4585059 0.80 ADK (0.40) ADORA1ADORA2ALTA4HALDH1A1KDM4E
SCHEMBL9773323 0.80 CES1 (0.40) ALDH1A1MAPTRAB9ANPC1MEN1
SCHEMBL30536884 0.80 LTA4H (0.50) LTA4HALDH1A1KDM4EMAPTHPGD
SCHEMBL29244541 0.80 LTA4H (0.37) ADORA1ADORA2ALTA4HALDH1A1KDM4E
SCHEMBL15972026 0.79 NEK2 (0.34) ALDH1A1KDM4ERAB9ANPC1KMT2A
SCHEMBL1224490 0.79 KDM4E (0.40) ALDH1A1KDM4EMAPTHTTMEN1
SCHEMBL4585770 0.79 KDM4E (0.40) ALDH1A1KDM4EMAPTHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334391-B2 Functionalized heteroacenes XEROX CORPORATION (US) 2012-12-18 US claimed
US-7372071-B2 Functionalized heteroacenes and electronic devices generated therefrom XEROX CORPORATION (US) 2008-05-13 US claimed
US-20070260069-A1 Functionalized heteroacenes XEROX CORPORATION 2007-11-08 US claimed
US-20070235721-A1 Functionalized heteroacenes and electronic devices generated therefrom XEROX CORPORATION 2007-10-11 US claimed
EP-1843410-B1 Functionalized heteroacenes and electronic devices generated therefrom XEROX CORP (US) 2013-10-16 EP disclosed
EP-1843410-A2 Functionalized heteroacenes and electronic devices generated therefrom Xerox Corporation (US) 2007-10-10 EP disclosed
EP-0261837-B1 Process for the preparation of electrically conductive material SANYO ELECTRIC CO (JP) 2001-07-11 EP disclosed
US-4795687-A POLYTHIENYLENE, POLYPRYRROLE OR POLYANILINE MATERIAL PREPARED BY OXIDATION POLYMERIZATION MITSUBISHI KASEI CORP. (JP) 1989-01-03 US disclosed
EP-0261837-A2 Electrically conductive material and a process for the preparation of same and secondary battery using the electrically conductive material Sanyo Electric Co., Ltd (JP) 1988-03-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070260069-A1 Functionalized heteroacenes SOD1, AHR, NR0B2 ADORA1 2934/4885ADORA2A 2322/4885LTA4H 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.